NASDAQ
31.10.25 | 20:59
4,410 US-Dollar
+1,85 % +0,080
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Do | Foghorn advances protein degrader programs for cancer treatment | 1 | Investing.com | ||
| Do | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs | 101 | GlobeNewswire (Europe) | - Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors... ► Artikel lesen | |
| Do | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.10. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit | 94 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen | |
| 05.08. | Foghorn: EPS übertrifft Schätzungen um 0,07 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch | ||
| 05.08. | Foghorn Therapeutics reports Q2 results | 3 | Seeking Alpha | ||
| 05.08. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.08. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.08. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update | 202 | GlobeNewswire (Europe) | FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track... ► Artikel lesen | |
| 01.07. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Citizens JMP reiterates Foghorn stock with $9 target | 2 | Investing.com | ||
| 14.05. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 14.05. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting | 146 | GlobeNewswire (Europe) | - FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical... ► Artikel lesen | |
| 06.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook | 158 | GlobeNewswire (Europe) | First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary... ► Artikel lesen | |
| 16.12.24 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | 205 | GlobeNewswire (Europe) | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
| 04.11.24 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update | 248 | GlobeNewswire (Europe) | First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in SMARCA4(BRG1) mutated NSCLC Topline Phase 1 dose escalation... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,80 | +0,17 % | Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen | DJ Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen
Von Dylan Tokar und Peter Loftus
DOW JONES--Novartis will den US-Biotech-Konzern Avidity Biosciences für 12 Milliarden... ► Artikel lesen | |
| QIAGEN | 40,760 | +0,90 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| CABALETTA BIO | 3,625 | +47,66 % | Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials | ||
| RECURSION PHARMACEUTICALS | 5,500 | -2,31 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 8,560 | +1,66 % | Morning Market Movers: Ventyx Biosciences, Brera Holdings, Safe & Green Holdings, American Rebel Holdings See Big Swings | CANBERA (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,185 | +52,80 % | Rani Therapeutics schließt Privatplatzierung ab und besetzt Vorstand neu | ||
| DYNE THERAPEUTICS | 22,580 | -4,08 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| BEAM THERAPEUTICS | 24,995 | +5,09 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| IMMUNOVANT | 24,700 | -0,44 % | Immunovant gains amid takeover speculation | ||
| ARCUTIS BIOTHERAPEUTICS | 25,320 | +1,61 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 81,40 | +3,75 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,900 | +1,45 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 33,320 | +3,25 % | Structure Therapeutics stock rating reiterated at Piper Sandler ahead of key data | ||
| PRIME MEDICINE | 4,950 | +13,79 % | Prime Medicine, Inc.: Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy |
Das Unternehmen FOGHORN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,410 Euro und damit +1,85 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FOGHORN THERAPEUTICS INC finden Sie auf Wallstreet Online.